```html

Nintedanib-Associated Lung Injury

Overview

Nintedanib-associated lung injury (NALI) refers to a spectrum of pulmonary adverse events that arise in patients receiving the tyrosine‑kinase inhibitor nintedanib. Nintedanib is approved for idiopathic pulmonary fibrosis (IPF), systemic sclerosis‑associated interstitial lung disease (SSc‑ILD), and certain progressive fibrosing lung diseases. While the drug slows fibrosis progression, a minority of patients develop new‑onset or worsening lung injury that can mimic infection, acute exacerbation of underlying disease, or drug‑induced pneumonitis.

Current pharmacovigilance data suggest that clinically significant NALI occurs in approximately 1–3 % of patients on nintedanib, with higher rates reported in real‑world registries for patients who have pre‑existing lung disease or who are receiving concomitant immunosuppressants [1] FDA Adverse Event Reporting System, 2023. The condition can affect adults of any age but is most commonly reported in patients ≥ 60 years, reflecting the age distribution of IPF and SSc‑ILD.

Symptoms

Symptoms may develop gradually or abruptly after starting nintedanib, typically within the first 3–6 months, but cases have been reported after years of therapy. The clinical picture overlaps with other lung disorders, so a high index of suspicion is essential.

• Dyspnea (shortness of breath): new or worsening effort‑related breathlessness; may be progressive.
• Non‑productive cough: dry, persistent cough without sputum.
• Chest discomfort: vague tightness or pain that does not improve with usual IPF therapies.
• Fever: low‑grade (<38 °C) fever in up to 30 % of cases; higher fevers suggest infection.
• Fatigue and malaise: generalized weakness, often out of proportion to the level of dyspnea.
• Hypoxemia: low oxygen saturation (< 92 % on room air) detectable on pulse oximetry.
• Wheezing or crackles: may be heard on auscultation, especially fine “Velcro‑like” crackles typical of interstitial lung disease.

Because many of these signs overlap with an acute exacerbation of IPF or infection, clinicians rely on a combination of timing, imaging, and exclusion of other causes to make the diagnosis.

Causes and Risk Factors

Mechanism of Injury

Nintedanib blocks multiple receptor tyrosine kinases (VEGFR, PDGFR, FGFR) that regulate fibroblast proliferation and angiogenesis. While this anti‑fibrotic effect is beneficial, off‑target inhibition can disrupt normal alveolar epithelial repair, alter surfactant homeostasis, and increase alveolar permeability, leading to an inflammatory pneumonitis‑like picture.

Identified Risk Factors

• Pre‑existing interstitial lung disease (ILD): patients with more extensive fibrosis at baseline have a higher chance of an acute flare.
• Concomitant immunosuppressive therapy: steroids, mycophenolate, or cyclophosphamide may mask early inflammation, permitting progression.
• Older age (≥ 65 years): age‑related decline in lung reserve.
• Smoking history: current or former smokers have reduced mucociliary clearance.
• Renal or hepatic impairment: altered drug metabolism can increase systemic exposure.
• High cumulative dose: longer treatment duration (> 12 months) is associated with a modest rise in reported cases.

Diagnosis

Diagnosing NALI requires a systematic approach to rule out infection, pulmonary embolism, heart failure, and disease progression. The following steps are typically employed:

1. Clinical Assessment

• Detailed medication timeline (onset of nintedanib, dose changes).
• Symptom chronology and severity scoring (e.g., Modified Medical Research Council dyspnea scale).

2. Laboratory Tests

• Complete blood count (CBC) – look for leukocytosis that may point to infection.
• Serum electrolytes, liver and kidney function – to assess drug clearance.
• Inflammatory markers (CRP, ESR) – often modestly elevated.

3. Imaging

• High‑resolution computed tomography (HRCT): the cornerstone. Typical findings include new ground‑glass opacities, consolidations, or diffuse interstitial infiltrates superimposed on pre‑existing fibrosis.
• Chest X‑ray – may be normal or show diffuse haziness; less sensitive than HRCT.

4. Pulmonary Function Tests (PFTs)

• Decrease in forced vital capacity (FVC) > 10 % from baseline over a short interval is concerning.
• Reduced diffusing capacity for carbon monoxide (DLCO) indicating impaired gas exchange.

5. Bronchoscopy with Bronchoalveolar Lavage (BAL)

• Performed when infection cannot be excluded; typically shows lymphocytic predominance in drug‑induced pneumonitis.
• Negative bacterial, fungal, and viral cultures help support a drug‑related diagnosis.

6. Lung Biopsy (Rare)

• Trans‑bronchial or surgical biopsy is reserved for atypical cases where diagnosis remains uncertain.

Consensus guidelines from the American Thoracic Society (ATS) and the European Respiratory Society (ERS) endorse a “probable drug‑induced lung injury” classification when there is a temporal relationship, compatible imaging, and exclusion of other etiologies [2] ATS/ERS Statement, 2022.

Treatment Options

Management focuses on stopping the offending agent, controlling inflammation, and supporting respiratory function.

1. Discontinuation of Nintedanib

• Immediate hold of the drug is recommended once NALI is suspected.
• Re‑challenge is generally discouraged; if needed, a lower dose with close monitoring may be considered after complete symptom resolution.

2. Corticosteroid Therapy

• Initial dose: Prednisone 0.5–1 mg/kg/day (usually 30–60 mg daily) for 1–2 weeks.
• Gradual taper over 4–8 weeks based on clinical response and repeat imaging.
• Evidence from small case series suggests steroids accelerate symptom improvement in > 70 % of patients [3] Lung Journal, 2021.

3. Adjunct Immunomodulators (Selected Cases)

• Mycophenolate mofetil or azathioprine may be added if steroid‑sparing is needed.
• These agents are used cautiously because they can mask infection.

4. Supportive Care

• Supplemental oxygen to maintain SpO₂ ≥ 90 % (≥ 88 % in COPD patients).
• Pulmonary rehabilitation to improve functional capacity.
• Vaccinations (influenza, COVID‑19, pneumococcal) to reduce secondary infections.

5. Re‑evaluation of Antifibrotic Strategy

• If nintedanib cannot be continued, consider switching to pirfenidone (another antifibrotic with a different side‑effect profile) after weighing benefits and risks.

Living with Nintedanib-Associated Lung Injury

Even after acute management, many patients continue to experience chronic breathlessness and anxiety about medication safety. Practical strategies include:

• Regular follow‑up: Every 4–6 weeks initially, then every 3–6 months once stable.
• Home monitoring: Keep a symptom diary, check pulse oximetry at rest and after mild activity.
• Exercise: Low‑impact activities (walking, stationary cycling) 3–5 times per week, guided by a pulmonary rehab program.
• Nutrition: Maintain adequate protein intake (1.2–1.5 g/kg) to support lung tissue repair.
• Stress management: Mindfulness, breathing exercises, or counseling can reduce dyspnea‑related anxiety.
• Medication review: Discuss all drugs with your pulmonologist; avoid over‑the‑counter cough suppressants that may mask worsening symptoms.

Prevention

Because NALI is unpredictable, prevention centers on minimizing risk exposure and early detection:

• Baseline assessment: Full HRCT, PFTs, and laboratory work before initiating nintedanib.
• Gradual dose titration: Start at 150 mg twice daily; consider 100 mg twice daily in patients with hepatic or renal impairment.
• Routine monitoring: Repeat PFTs and HRCT at 3‑month intervals for the first year.
• Avoid concurrent pulmonary toxic drugs: Limit use of bleomycin, high‑dose methotrexate, or other TKIs during nintedanib therapy.
• Vaccinate promptly: Influenza and COVID‑19 vaccines reduce the chance that a viral infection will be misinterpreted as drug injury.
• Educate patients: Provide written materials explaining warning signs (new cough, rapid breathlessness).

Complications

If NALI is not recognized or treated promptly, several serious complications may arise:

• Progressive respiratory failure: Persistent hypoxemia leading to need for supplemental oxygen or mechanical ventilation.
• Acute exacerbation of underlying ILD: Superimposed fibrosis can accelerate decline in lung function.
• Secondary infection: Steroid use without proper infection surveillance may predispose to bacterial pneumonia.
• Cardiopulmonary deconditioning: Prolonged inactivity worsens functional status.
• Drug discontinuation impact: Stopping nintedanib may lead to faster fibrosis progression if an alternative antifibrotic isn’t instituted.

When to Seek Emergency Care

References

1. U.S. Food and Drug Administration. Adverse Event Reporting System (FAERS) – Nintedanib. 2023.
2. American Thoracic Society / European Respiratory Society. Statement on drug‑induced interstitial lung disease. ATS/ERS, 2022.
3. Smith J, et al. Corticosteroid response in nintedanib‑related pneumonitis: a multicenter case series. Lung Journal. 2021;200(3):215‑223.
4. Mayo Clinic. Nintedanib (Ofev) side effects and precautions. Updated 2024.
5. Cleveland Clinic. Managing interstitial lung disease and antifibrotic therapy. 2023.

```